Loading...
•
Sep 30, 2024
CVRx Q3 2024 Earnings Report
CVRx's third quarter performance in 2024 showed strong revenue growth driven by increased adoption of Barostim therapy and favorable reimbursement news.
Key Takeaways
CVRx reported a 27% increase in revenue for Q3 2024, driven by growth in the U.S. heart failure business. The company saw increases in active implanting centers and sales territories. Gross profit also increased, while R&D expenses decreased. The company expects revenue between $14.5 million and $15.5 million for the fourth quarter of 2024.
Revenue increased by 27% to $13.4 million compared to Q3 2023.
U.S. revenue increased by 28% to $12.3 million, driven by growth in the heart failure business.
Gross profit increased by 26% to $11.1 million, with a gross margin of 83%.
The company expects revenue between $14.5 million and $15.5 million for the fourth quarter of 2024.
CVRx
CVRx
CVRx Revenue by Geographic Location
Revenue by Geographic Location
U.S. Revenue
CapyFin.comEurope Revenue
CapyFin.com Forward Guidance
The Company expects to report total revenue between $14.5 million and $15.5 million for the fourth quarter of 2024.
Revenue & Expenses
Visualization of income flow from segment revenue to net income